Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin‐2

To investigate the impact of intermittent interleukin‐2 (IL‐2) plus combination antiretroviral therapy (cART) on HIV‐1 entry co‐receptor use.

[1]  S. Pett.  Immunotherapies in HIV-1 infection , 2009, Current opinion in HIV and AIDS.

[2]  K. Henry.  Report from the 16th Conference on Retroviruses and Opportunistic Infections. No clinical benefit from adding IL-2 to ART. , 2009, Journal watch. AIDS clinical care.

[3]  R. Davey,et al.  Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial , 2009, AIDS.

[4]  IL-2 therapy provides no clinical benefit to HIV-infected patients on ART. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  L. Stuyver,et al.  HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. , 2007, Journal of virological methods.

[6]  N. Meanwell,et al.  Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. , 2007, Current opinion in investigational drugs.

[7]  T. Melby.  HIV coreceptor use in heavily treatment-experienced patients: does it take two to tangle? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  E. Fenyö,et al.  Frequent Intrapatient Recombination between Human Immunodeficiency Virus Type 1 R5 and X4 Envelopes: Implications for Coreceptor Switch , 2007, Journal of Virology.

[9]  David W. Williamson,et al.  Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.

[10]  Douglas A. Hosack,et al.  Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. , 2005, The Journal of clinical investigation.

[11]  D. Follmann,et al.  Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. , 2004, Blood.

[12]  R. Paredes,et al.  The potential role of interleukin-2 in patients with HIV infection. , 2002, AIDS reviews.

[13]  A. Lazzarin,et al.  Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy. , 2001, The Journal of infectious diseases.

[14]  C. Tomino,et al.  Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment. , 2000, Antiviral research.

[15]  J. Kovacs,et al.  Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. , 2000, The Journal of infectious diseases.

[16]  D. Weissman,et al.  Interleukin-2 up-regulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. , 2000, The Journal of infectious diseases.

[17]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.

[18]  B. Clotet,et al.  Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. , 1999, AIDS.

[19]  A. Foussat,et al.  Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. , 1999, AIDS.

[20]  H. Schuitemaker,et al.  Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. , 1999, The Journal of infectious diseases.

[21]  S. Zolla-Pazner,et al.  Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor , 1997, Journal of virology.

[22]  C. Mackay,et al.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Baggiolini,et al.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.

[24]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[25]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[26]  B. Larder,et al.  HIV‐1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment , 1992, AIDS.